Trial results

$ACRS — Bosakitug (ATI-045)

Aclaris Therapeutics, Inc. (ACRS) Bosakitug (ATI-045): trial results in Atopic dermatitis, 2026.

Research by Catalyst Intel

The catalyst

"Bosakitug (ATI-045) Anti-TSLP monoclonal antibody Phase 2 top line results in AD: 4Q 2026"

— Aclaris Therapeutics, Inc., 8-K filed 2026-10-27 · the filing. Checked word for word against the stored document when this page was built; a sentence that did not check out would not be here.

Event id

ACRS-BOSAKITUGATI-2026

Company

Aclaris Therapeutics, Inc.

Kind

Trial results

Indication

Atopic dermatitis

Window

2026-10-01 – 2026-12-31

Status

dropped

The bar

No bar has been published for this event yet.

Verdicts

No verdict has been published for this event yet.